CD22 and precursor B-cell acute lymphoblastic leukemia: A retrospective analysis of 628 B-ALL patients found that approximately 17% harbored CD19-negative and 22% had CD22-negative leukemic clones prior to CAR-T therapy (Rosenthal et al., 2018; Lin et al., 2024).